ESPR vs IDXX · rev $403.1M vs P/E 40, rev $2.36B
Esperion Therapeutics Inc (ESPR) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported ESPR revenue for 2025-12-31 was $403.1M. Net income was -$22.7M. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. ESPR currently screens at market cap $816.9M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
ESPR currently screens at market cap $816.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the ESPR and IDXX stock pages for the full models.
Not investment advice.